TCBPY (TC BioPharm (Holdings)) Common Stock: $0.32 Mil (As of Dec. 2024)


What is TC BioPharm (Holdings) Common Stock?

TC BioPharm (Holdings) TCBPY Common Stock is $0.32 Mil as of Dec. 2024.

TC BioPharm (Holdings)'s quarterly common stock increased from Dec. 2023 ($0.00 Mil) to Jun. 2024 ($0.01 Mil) and increased from Jun. 2024 ($0.01 Mil) to Dec. 2024 ($0.32 Mil).

TC BioPharm (Holdings)'s annual common stock increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil) and increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.32 Mil).

TC BioPharm (Holdings) Common Stock Historical Data

* Premium members only.

The historical data trend for TC BioPharm (Holdings)'s Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TC BioPharm (Holdings) Common Stock Chart

TC BioPharm (Holdings) Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Common Stock
Get a 7-Day Free Trial 0.26 0.26 0.00 0.00 0.32

TC BioPharm (Holdings) Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.50 0.00 0.01 0.32

TC BioPharm (Holdings) Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.32 Mil mean?
TC BioPharm (Holdings) (TCBPY) has a Common Stock of $0.32 Mil as of Dec. 2024. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on TC BioPharm (Holdings) and its competitors.
Is TC BioPharm (Holdings)'s Common Stock too high?
TC BioPharm (Holdings)'s current Common Stock is $0.32 Mil.
How does TC BioPharm (Holdings)'s Common Stock compare to SIGY and CNBX?
TC BioPharm (Holdings)'s Common Stock of $0.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on TC BioPharm (Holdings) and its competitors. TC BioPharm (Holdings)'s current Common Stock is $0.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TC BioPharm (Holdings) stock overvalued right now?
TC BioPharm (Holdings) (TCBPY) has a current Common Stock of $0.32 Mil. The current Common Stock is $0.32 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For TC BioPharm (Holdings) (TCBPY), the current Common Stock is $0.32 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TC BioPharm (Holdings) Business Description

Address Maxim 1, 2 Parklands Way, Holytown, Motherwell, Scotland, GBR, ML1 4WR
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.